B Cells in Patients With Melanoma: Implications for Treatment With Checkpoint Inhibitor Antibodies.

ABSTRACT: The contributions of the humoral immune response to melanoma are now widely recognized, with reports of positive prognostic value ascribed to tumor-infiltrating B cells (TIL-B) and increasing evidence of B cells as key predictors of patient response to treatment. There are disparate views as to the pro- and anti-tumor roles of B cells. B cells appear to play an integral role in forming tumor-associated tertiary lymphoid structures (TLSs) which can further modulate T cell activation. Expressed antibodies may distinctly influence tumor regulation in the tumor microenvironment, with some isotypes associated with strong anti-tumor immune response and others with progressive disease. Recently, B cells have been evaluated in the context of cancer immunotherapy. Checkpoint inhibitors (CPIs), targ

SUBMITTER: Willsmore ZN 

PROVIDER: S-EPMC7868381 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature